文献リスト

1) Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006; 41: 17-27

2) McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339: 1485-92

3) Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998; 352: 1426-32

4) Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339: 1493-9

5) Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358: 958-65

6) Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347: 975-82

7) Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140: 346-55

8) Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004; 40: 993-9

9) 飯野四郎, 沖田 極, 小俣政男, 他. Genotype 1かつ高ウイルス量のC型慢性肝炎に対するPEG-インターフェロンα-2bとリバビリン48週併用療法の有用性-インターフェロンα-2bとリバビリン6ヶ月併用療法とのretrospectiveな比較─. 肝胆膵. 2004; 49: 1099-121

10) 熊田博光, 豊田成司, 後藤賢一郎, 他. Genotype 1かつ低ウイルス量, あるいはgenotype 2のC型肝炎に対するPEG-インターフェロンα-2bとリバビリン24週併用療法の有効性─インターフェロンα-2bとリバビリン24週間併用療法との比較─. 肝胆膵. 2006; 52: 645-63

11) 平松直樹, 小瀬嗣子, 林 紀夫. C型肝炎に対するPEG-IFN/リバビリン併用療法の進歩 ウイルス遺伝子型の違いによる治療法の実際 Genotype 1型かつ高ウイルス量症例─臨床薬理試験から─. 肝胆膵. 2006; 53(増刊号): 9-14

12) 泉 並木. C型肝炎に対するPEG-IFN/リバビリン併用療法の進歩 ウイルス遺伝子型の違いによる治療法の実際 Genotype 2型症例 ─Genotype 2型に対する試験および薬物動態試験を中心に─. 肝胆膵. 2006; 53(増刊号): 15-24

13) Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006; 130: 1086-97

14) Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006; 131: 451-60

15) Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology. 2007; 46: 1688-94

16) Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology. 2008; 47: 43-50

17) Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008; 47: 1884-93

18) Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology. 2007; 46: 1732-40

19) Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastoroenterology. 2008; 135: 451-8

20) Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007; 357: 124-34

21) Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008; 47: 35-42

22) Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 2008; 47: 1837-45

23) Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006; 131: 997-1002

24) Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007; 132: 1767-77

25) Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 2007; 46: 640-8

26) Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology. 2007; 46: 631-9

27) Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008; 49: 163-9

28) Mchutchison JG, Everson GT, Gordon SC, et al. PROVE1: Results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C. J Hepatol. 2008; 48(Suppl 2): S4

29) Dusheiko GM, Hezode C, Pol S, et al. Treatment of chronic hepatitis C with telaprevir in combination with peginterferon-alfa-2a with or without ribavirin: further interim analysis results of the PROVE 2 study. J Hepatol. 2008; 48(Suppl 2): S26

30) Hezode C, Ferenci P, Dusheiko GM, et al. PROVE2: Phase 2 study of VX950 (telaprevir) in combination with peginterferon alfa2a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis. Hepatology. 2007; 46(Suppl 1): 268A

31) Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology. 2007; 132: 1270-8

32) Kwo P, Lawitz E, McCone J, et al. Interim results from HCV sprint-1: RVR/EVR from phase 2 study of boceprevir plus pegintronTM (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 CHC. J Hepatol. 2008; 48(Suppl 2): S372

33) Reesink H, Verloes R, Abou K, et al. Safety of the HCV protease inhibitor tmc435350 in healthy volunteers and safety and activity in chronic hepatitis c infected individuals: a phase 1 study. J Hepatol. 2008; 48(Suppl 2): S28-29

34) Pierra C, Amador A, Benzaria S, et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. J Med Chem. 2006; 49: 6614-20

35) Poordad F, Lawits EJ, Gitlin N, et al. Efficacy and safety of valopicitabine in combination with pegylated interferon-α and ribavirin in patients with chronic hepatitis C. Hepatology. 2007; 46(Suppl 1): 866A

36) Roberts SK, Cooksley G, Dore GJ, et al. Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology. 2008; in press

37) Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology. 2008; in press

38) Lalezari J, Gane E, Rodriguez-Torres M, et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with peg-IFN and ribavirin: interim results of R7128 500mg bid for 28 days. J Hepatol. 2008; 48(Suppl 2): S29

39) Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007; 132: 103-12

40) Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol. 2007; 5: 124-9

41) Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology. 2006; 131: 1040-8

42) Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. 2007; 46: 371-9

43) Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007; 46: 971-81

44) Jacobson IM, Brown RS, Jr., McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. 2007; 46: 982-90

45) Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology. 2008; 47: 1453-61

46) Fried MW, Jensen D, Rodriguez-Torres M, et al. Improved outcomes in hepatitis C patients with difficult to treat characteristics: Randomized study of higher doses of peginterferon α-2a and ribavirin. Hepatology. 2008; 48: 1033-43

47) Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007; 46: 403-10

48) Akuta N, Suzuki F, Kawamura Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2007; 79: 1686-95

49) Welker MW, Hofmann WP, Welsch C, et al. Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon-alpha-based therapy in HCV-1b-infected patients. J Viral Hepat. 2007; 14: 338-49

50) El-Shamy A, Nagano-Fujii M, Sasase N, et al. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology. 2008; 48: 38-47

51) Asahina Y, Izumi N, Hirayama I, et al. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. Gastroenterology. 2008; 134: 1396-405

52) Randall G, Chen L, Panis M, et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology. 2006; 131: 1584-91

53) Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006; 43: 954-60

54) Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004; 40: 1260-5

55) Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005; 352: 2609-17

56) von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005; 129: 522-7

57) McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002; 123: 1061-9

58) Zeuzem S, Yoshida EM, Benhamou Y, et al. Albinterferon alfa-2b dosed every 2 or 4 weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology. 2008; 48: 407-17

59) Gish RG, Arora S, Rajender Reddy K, et al. Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol. 2007; 47: 51-9

60) McHutchison JG, Bacon BR, Gordon SC, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology. 2007; 46: 1341-9

61) Horsmans Y, Berg T, Desager JP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology. 2005; 42: 724-31

62) Kerr B, Bauman L, Webber S, et al. Phalmacokinetics, safety, and tolerability of the isatoribine oral prodrug ANA975 in phase 1 healthy volunteer study. Hepatology. 2005; 42(Suppl. 1): 533A

63) Firbas C, Jilma B, Tauber E, et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine. 2006; 24: 4343-53

64) Klade CS, Wedemeyer H, Berg T, et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology. 2008; 134: 1385-95

65) Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology. 2004; 127: 1347-55

66) Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005; 41: 832-5

67) Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 2008; 77: 56-63

68) Rossignol JF, Kabil SM, El-Gohary Y, et al. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2008; in press

69) Rossignol JF, Elfert A, El-Gohary Y, et al. Randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4. J Hepatol. 2008; 48(Suppl 2): S30

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp